A recent paper (43(5):959-73, 2015) from the Burton lab was featured on the cover of the November 17, 2015, issue of Immunity. Andrabi et. al. compared four prototypes of V2 apex broadly neutralizing antibodies and showed that all four recognized a core epitope of basic V2 residues and glycan-N160. Additionally, two of these prototypes were derived from germlines that are 99% identical and used a common germline to interact with the V2-epitope. Overall, these studies indicate a potential strategy to transition from antibody panels to vaccine candidates.